Trump’s Executive Order on Drug Prices Might Be More in Favour of Drug Companies

The order will likely be a far cry from the president’s previous remarks about the pharmaceutical industry.

Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six-page document outlining the draft provisions or objectives of a proposed presidential executive order on drug prices. She has shared some of the details, but only a few highlight; so the public still has limited information. Continue reading

Posted in Drug prices, Patent, Patent Term Extension, Uncategorized | Leave a comment

 The Government Created This Zika Vaccine. Why Should Big Pharma Reap the Profits?

 Lawmakers are concerned that giving a drug company a monopoly on the promising vaccine could make it unaffordable. 

Posted in Drug prices, Patent, R&D, Uncategorized | Leave a comment

In Thailand, patient activism is crucial to expanding treatment

Source: MSF| July 2004

Access to antiretrovirals in Thailand has increased eight-fold in the last three years, with 50,000 people due to receive treatment by the end of this year. People living with HIV/AIDS have been the crucial actors.

There are currently more than 700 groups of people with HIV/AIDS in Thailand, mostly hospital-based and government-funded, co-ordinated by TNP , the Thai Network for People Living with HIV/AIDS. Particularly crucial has been their support for the production of generic antiretrovirals (ARVs) by the Government Pharmaceutical Organisation. Continue reading

Posted in Uncategorized | Leave a comment

The Trump Executive Order on drug prices: not what was promised nor needed, and contrary to US self interest

Source: Medium

Emily Kopp has a big scoop for Kaiser Health News. She has obtained a six page document outlining the draft provisions or objectives of a proposed Presidential Executive Order (EO) on drug prices. She has shared some of the details, but only a few highlights., so the public still has limited information.

The first of the “principles” and “talking points” she reported is as follows:

Extending the patent life of drugs in foreign markets to “provide for protection and enforcement of intellectual property rights.” This will ensure “that American consumers do not unfairly subsidize research and development for people throughout the globe.”

We don’t know which foreign markets this involves, but one can guess. Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

June 2017 Alert: Pressure on countries hiked by US on IP

The US government is stepping up on TRIPS plus pressure through bilateral forums based on a US law that passed under Obama to strengthen IPR enforcement and the 301 process. Countries targeted include India, Indonesia, China, Thailand, Ukraine in Asia and Argentina, Chile and Venezuela in Latin America.

Most likely this will be public when USTR sends a report to congress (potentially this month). Indonesia and Argentina are already being made aware of the list of demands by USTR.  Continue reading

Posted in Compulsory Licensing, Data Exclusivity, Evergreening, IPR Enforcement, Special 301 report, Uncategorized, UNHLP report, US Pressure | Leave a comment

How RCEP affects food and farmers

Source: GRAIN

The Regional Comprehensive Economic Partnership (RCEP) is a mega-regional trade deal being negotiated among 16 countries across Asia-Pacific. If adopted, RCEP will cover half the world’s population, including 420 million small family farms that produce 80% of the region’s food. RCEP is expected to create powerful new rights and lucrative business opportunities for food and agriculture corporations under the guise of boosting trade and investment. Several RCEP countries are also part of the Trans-Pacific Partnership (TPP), another mega-regional agreement setting some of the most pro-big business terms seen in trade and investment deals so far. While the fate of the TPP is uncertain, these two agreements may have to co-exist and there is pressure to align them on numerous points. What will this mean for food and farmers in the region? Continue reading

Posted in Regional Comprehensive Economic Partnership, Uncategorized | Leave a comment

TRIPS Council Members: Defining IP Rights And The Public Interest

Source: IPWatch

“Political and economic pressure placed on governments to forgo the use of TRIPS flexibilities violates the integrity and legitimacy of the system of legal duties and rights created by the TRIPS agreement and as reaffirmed by the Doha Declaration,” India told a World Trade Organization committee this week, referring to the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Continue reading

Posted in Compulsory Licensing, TRIPS, TRIPS flexibilities, Uncategorized | Leave a comment